| Status | Discontinued |
| Decision | Selected |
| Process | TA |
| Referral date | 01 June 2004 |
| Topic area |
|
| Description |
The Technology Appraisal of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis after failure of a previous TNF-α inhibitor ended following the publication of the appeal panel decision in November 2008. The Institute decided that a new appraisal of the above TNF-α inhibitors should be scheduled into the work programme and combined with a review of technology appraisalguidance 126 (rituximab) and 141 (abatacept). |
Provisional Schedule
| Final scope published: | November 2004 |
| 1st appraisal committee meeting: | 03 April 2008 |
| 2nd appraisal committee meeting: | 03 June 2008 |
Project Team
| Assessment Group / Evidence Review Group: | West Midlands Health Technology Assessment Collaboration |
| Communications manager: | Tonya Gillis |
| Executive Lead: | Andrew Dillon |
| Project manager: | Jeremy Powell |
| Technical Lead: | Zoe Garrett |
Stakeholders
| Department of Health | Eastern Hull PCT |
| Somerset Coast PCT | |
| Welsh Assembly Government | |
| Manufacturers / Sponsors | Abbott Laboratories Ltd (adalimumab) |
| Wyeth Pharmaceuticals (etanercept) | |
| Schering-Plough Ltd (infliximab) | |
| Patient / Carer Groups | Arthritis and Musculoskeletal Alliance |
| Arthritis Care | |
| Arthritis Research Campaign | |
| Back Care | |
| Long Term Medical Conditions Alliance | |
| National Rheumatoid Arthritis Society | |
| Professional Groups | British Association of Spine Surgeons |
| British Health Professionals in Rheumatology | |
| British Institute of Musculoskeletal Medicine | |
| British Orthopaedic Association | |
| British Society for Rheumatology | |
| Primary Care Rheumatology Society | |
| Royal College of Nursing | |
| Royal College of Physicians | |
| Royal Pharmaceutical Society | Others |
| Assessment Team | West Midlands Health Technology Assessment Collaboration |
| National Coordinating Centre for Health Technology Assessment | |
| Associated Guideline Groups | None |
| Associated Public Health Groups | None |
| Comparator Manufacturers | Roche |
| General | Board of Community Health Councils in Wales |
| Medicines and Healthcare products Regulatory Agency (MHRA) | |
| National Public Health Service for Wales | |
| NHS Quality Improvement Scotland | |
| British National Formulary | |
| Research Groups | None |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 19 October 2007 | Following the appeal decision the Technology appraisal split. First use of TNF inhibitors published as TA130. As per appeal instruction sequential use of treatments to be discussed by the committee after additional analysis complete. |
| 31 January 2008 | Stakeholders invited to comment on the technical content of the additional analysis produced. |
| 24 November 2008 |
The Appeal Panel met on 29 September 2008 to consider the appeals lodged against the Final Appraisal Determination (FAD) for this appraisal. The decision of the appeal panel can be found below. The appeal was upheld under grounds 1 and 2 and the appeal panel has recommended that the appraisal of the sequential use of the three drugs after failure of the first TNF inhibitor should be restarted as a new appraisal. We have written to the Department of Health to ask whether they want us to do this and we will update this page of the web site when we have their response. As a consequence of the appeal panel's decision, this appraisal is now ended. |
For further information on our processes and methods, please see our CHTE processes and methods manual